The reassessment of Leqembi’s safety data follows the agency’s previous recommendation of the drug for use in the EU.

Children who inherit genetic mutations from parents with early-onset Alzheimer’s typically show signs of dementia at the same ...

European Union regulators will review new information relating to the safety of Eisai Co.’s and Biogen Inc.’s medicine for ...

The European Commission has requested its medicines regulator to consider safety information on Eisai and Biogen's ...

Scientists are testing an experimental anti-amyloid antibody in people expected to develop early-onset Alzheimer's.

II-73, has the potential to restore memory and cognitive function in a mouse model of Alzheimer's disease. The study demonstrates that the drug improves memory deficits and reverses brain cell damage, ...

A paradigm-shifting study from the Centre for Addiction and Mental Health (CAMH) shows an experimental drug, GL-II-73, has ...

Readers worry that fraud may tarnish the field and slow the race for a cure. Also: Charles Blow’s farewell; treatment for ...

The Washington University trial comes as part of a larger platform study which hopes to understand if Alzheimer's disease can ...

Following the president’s recent executive order dismantling diversity, equity, and inclusion policies, the main page for the ...